Chung-Yi Liu
Overview
Explore the profile of Chung-Yi Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chang Y, Lin P, Chen C, Weng W, Yu K, Liu C, et al.
Exp Ther Med
. 2021 Sep;
22(5):1204.
PMID: 34584549
The present study investigated the role of tubulin polymerization promoting protein (TPPP) in the regulation of bladder cancer (BC) cell proliferation and migration, in addition to the association between TPPP...
12.
Shih C, Chang C, Liu C, Wu H
Biomicrofluidics
. 2021 Sep;
15(5):054101.
PMID: 34504638
In this study, a viscometer, which can measure the viscosity of low-volume liquids (25 l) within 30 s, was developed on a centrifugal platform. The centrifugal viscometer consists of a...
13.
Lin Y, Lin P, Shao I, Chu Y, Kan H, Liu C, et al.
J Oncol
. 2021 Sep;
2021:9648579.
PMID: 34484340
Background: The present study aimed to analyse factors influencing the effects of androgen deprivation therapy (ADT) in patients with newly diagnosed metastatic castration-naïve prostate cancer (mCNPC), especially in low-volume disease...
14.
Su S, Chang Y, Huang L, Chu Y, Kan H, Liu C, et al.
Tumori
. 2021 Apr;
108(3):270-277.
PMID: 33845702
Objective: Patients with positive surgical margins (PSMs) after radical prostatectomy for localized prostate cancer have a higher risk of biochemical failure (BCF). We investigated the risk factors of BCF in...
15.
Lin P, Huang C, Yu K, Kan H, Liu C, Chuang C, et al.
Oncol Lett
. 2021 Jan;
21(2):169.
PMID: 33456545
Kidney cancer is one of the most lethal cancer types worldwide. The most common subtype of kidney cancer is clear cell renal cell carcinoma (ccRCC), and the somatic mutations of...
16.
Li Y, Yu K, Chang Y, Lin P, Shao I, Kan H, et al.
Cancer Manag Res
. 2020 Sep;
12:7439-7450.
PMID: 32884355
Purpose: We investigate factors that may contribute individually to bladder recurrence and find out the potential candidate to receive postoperative single dose intravesical chemotherapy. Materials And Methods: A total of...
17.
Shao I, Kan H, Liu C, Lin P, Yu K, Pang S, et al.
Onco Targets Ther
. 2019 Oct;
12:8189-8196.
PMID: 31632069
Introduction: Surgery remains the standard treatment for localized renal cell carcinomas, and partial nephrectomy is considered before radical nephrectomy with the aim of preserving renal function. This study aimed to...
18.
Tseng J, Yang L, Lin Y, Liu C, Pang S, Hong J, et al.
Contrast Media Mol Imaging
. 2018 Dec;
2018:8945130.
PMID: 30532664
Purpose: Positron emission tomography/magnetic resonance imaging (PET/MRI) can facilitate the use of noninvasive imaging biomarkers in clinical prostate cancer staging. Although multiparametric MRI is a widely used technique, the clinical...
19.
Tsai C, Chen Y, Chang Y, Hsueh C, Liu C, Chang Y, et al.
Oncotarget
. 2018 Aug;
9(56):30731-30747.
PMID: 30112103
Bladder cancer biomarkers currently approved by the Food and Drug Administration are insufficiently reliable for use in non-invasive clinical diagnosis. Verification/validation of numerous biomarker candidates for BC detection is a...
20.
Chang Y, Chang S, Liu C, Lin P, Yu K, Pang S, et al.
Ther Clin Risk Manag
. 2018 Jul;
14:1235-1241.
PMID: 30038497
Introduction: Renal cell carcinoma (RCC) is one of the most lethal urological malignancies, and surgeries remain the mainstay for localized RCC. This study aimed to compare the selection of open...